Benzinga.com

EXCLUSIVE: Vivani Medical Subdermal Semaglutide Implant Shows 20% Weight Loss In Animal Study, With Potential For Once-Yearly Dosing

Vivani Medical, Inc. (NASDAQ:VANI), on Wednesday, released preclinical data for NPM-139, its subdermal semaglutide implant under development for chronic weight management in obese and overweight ...
Benzinga.com

EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows

Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for ...
New Atlas

Subdermal implant could boost islet cell therapy for diabetics

While islet cell transplants allow some diabetics to forgo daily insulin injections, those people have to take immunosuppressive drugs in order to keep the cells from being rejected. A new implant, ...
Nasdaq

Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021

Company to Proceed with Phase 2 Development Program for Islatravir Subdermal Implant “We are delighted to share our early data at CROI 2021 supporting the potential for a once-yearly dosing regimen ...
Business Wire

Merck Presents Results from Phase 1 Trial Evaluating Investigational Islatravir Subdermal Implant for the Prevention of HIV-1 Infection at CROI 2021

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a Phase 1 study evaluating the safety, tolerability and ...